Product
AI AGENTS
INTELLIGENCE SUITE
API, MCP & INTEGRATION
Solutions
INDUSTRIES
USE CASES
Pricing
Resources
EXPLORE
ENGAGE
SUPPORT & SERVICES
About
Patsnap Eureka Platform
IP Search Agents
IP Drafting Agents
Engineering Agents
Find Solutions with TRIZ
Life Sciences Agents
Materials Agents
SEP Agents
Patsnap Eureka Desktop
BetaAnalytics
IP IntelligenceSynapse
Biopharma IntelligenceBio
Biosequence Search and AnalysisChemical
Chemical Structure Search and AnalysisProfessional Services
Open Platform
Developer Center
Customer Stories
Newsroom
Blog
Global Innovation Report
Glossary
Free tools
NEWWebinars & Training
User Community
R&D Benchmark Calculator
Trust and Security
PatentBench
NEWLLM
Help center
Careers
Access to over 2,000,000,000 structured data points around patents, science, litigation, and tech sectors
Innovate 75% faster at 25% less cost
Cloud or on-prem for maximum privacy and control
Trusted by more than 18,000 innovators worldwide
To use , click the vertification button in the email we sent to [email protected].
This helps keep your account secure.
You should receive it shortly. Don’t forget to check your spam folder.
Already have an account? Log In
To start using Patsnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Thoughtfully curated series offering valuable insights for innovation professionals
Article | Report Map the 2026 AI protein structure prediction landscape: AlphaFold2, ESMFold, RoseTTAFold, antibody modeling, and emerging lightweight architectures for drug discovery.
Article | Report Nedosiran's FDA approval for primary hyperoxaluria type 1: how Dicerna/Novo Nordisk's LDHA-targeting siRNA competes with lumasiran in the RNAi oxalate space.
Article | Report How AstraZeneca is reformulating durvalumab (Imfinzi) for subcutaneous delivery using Halozyme ENHANZE technology — and what it means for the SC checkpoint inhibitor race.
Article | Report A 2026 landscape of advanced nuclear reactor fuel technology: ATF compositions, HALEU supply chains, REMIX recycling, TRISO fuels, and closed fuel cycle strategies.
Article | Report AbbVie's Rinvoq (upadacitinib) faces a pivotal 2026: expanding into atopic dermatitis and AS while navigating JAK inhibitor class-wide safety labeling scrutiny.
Article | Report Merck's Keytruda faces a 2028 patent cliff. Explore pembrolizumab successor pipeline, fixed-dose combinations, and ADC partnerships shaping the post-cliff strategy.
Article | Report A 2026 patent and literature landscape of wearable continuous health monitoring: key technology clusters, top assignees, emerging directions, and strategic implications.
Article | Report Capivasertib (AZD5363) targets the PI3K/AKT/PTEN pathway in HR+/HER2- breast cancer. Explore the CAPItello-291 Phase III rationale, IP signals, and combination strategy.
Article | Report An overview of tarlatamab's DLL3-targeting BiTE mechanism, the DeLLphi-312 first-line SCLC trial design, and IO + bispecific combination rationale for extensive-stage SCLC.
Article | Report Patritumab deruxtecan (HER3-DXd) is reshaping post-EGFR TKI NSCLC treatment. Explore the patent race, clinical data, and Daiichi Sankyo/AstraZeneca strategy.
Article | Report Explore the 2026 wearable continuous health monitor technology landscape: key patent trends, R&D signals, and innovation intelligence from PatSnap Eureka.
Article | Report LAG-3 combination therapy relatlimab plus nivolumab vs. pembrolizumab in adjuvant melanoma: checkpoint mechanisms, clinical context, and IP landscape analysis.
Article | Report TERN-501 is a selective THRβ agonist developed by Terns Pharmaceuticals for MASH. Explore its patent landscape, mechanism, and competitive positioning against resmetirom.
Article | Report Icotrokinra (JNJ-2113) is the first oral IL-23 receptor peptide inhibitor in Phase III for psoriasis. Explore J&J's patent strategy and the race to challenge injectable biologics.
Article | Report Iptacopan vs. ravulizumab in PNH: how oral Factor B inhibition reshapes complement therapy, hemoglobin endpoints, and the competitive landscape.